CS-7017

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neoplasm

Conditions

Neoplasm

Trial Timeline

Nov 1, 2006 → Feb 1, 2010

About CS-7017

CS-7017 is a phase 1 stage product being developed by Daiichi Sankyo for Neoplasm. The current trial status is completed. This product is registered under clinical trial identifier NCT00408434. Target conditions include Neoplasm.

What happened to similar drugs?

20 of 20 similar drugs in Neoplasm were approved

Approved (20) Terminated (3) Active (0)

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00881569Phase 1Completed
NCT00408434Phase 1Completed

Competing Products

20 competing products in Neoplasm

See all competitors
ProductCompanyStageHype Score
ADC-1013Alligator Bioscience ABPhase 1
19
FulvestrantDr. Reddy's LaboratoriesPre-clinical
19
AB0024Gilead SciencesPhase 1
29
TTI-237PfizerPhase 1
21
852APfizerPhase 1
29
EO-3021 + Ramucirumab (CYRAMZA®) + DostarlimabCSPC Pharmaceutical Group LimitedPhase 1
21
LY2780301Eli LillyPhase 1
29
PemetrexedEli LillyPhase 2
35
pemetrexed + cisplatinEli LillyPhase 1/2
32
IMC-3C5Eli LillyPhase 1
29
LY3295668Eli LillyPhase 1/2
32
Abemaciclib + ClarithromycinEli LillyPhase 1
29
Abemaciclib + FulvestrantEli LillyPhase 2
27
Galunisertib + Gemcitabine + PlaceboEli LillyPhase 1/2
32
Fulvestrant + AbemaciclibEli LillyPhase 2
39
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
44
Prexasertib + Cisplatin + Cetuximab + G-CSF + Pemetrexed + Fluorouracil + LY3023414 + LeucovorinEli LillyPhase 1
29
LY2784544Eli LillyPhase 1
29
Tadalafil + GemcitabineEli LillyPhase 1
29
enzastaurinEli LillyPhase 2
35